晚期恶性肿瘤血清VEGF含量测定的临床意义

目的：探讨血清血管内皮生长因子（VEGF）浓度在晚期恶性肿瘤中的临床意义。方法：应用酶联免疫吸附试验（ELISA）测定40例晚期恶性肿瘤（非小细胞肺癌、鼻咽癌、食管癌）患者血清的VEGF浓度，10名健康成人作为对照。结果：40例晚期恶性肿瘤患者血清VEGF浓度为（477．07±374．10）pg／ml，显著高于健康成人（139．09±133．41）pg／ml，差异有统计学意义（P=0．016），其中治疗前血清VEGF浓度在非小细胞肺癌为（518．53±378．99）pg／ml，食管癌为（399．21±393．69）pg／ml，鼻咽癌为（500．68±348．48）pg／ml，与健康成人比较差异有统计学意义（P值分别为0．011、0．044和0．019）。化疗有效患者的血清VEGF浓度（400．41±332．84）pg／ml显著低于化疗前浓度（777．10±666．01）pg／ml，差异有统计学意义（P=0．034）。结论：血清VEGF可作为晚期恶性肿瘤监测病情、判断放疗和预后一个有用的指标。

Clinical significance of serum vascular endothelial growth factor in advanced malignant tumors

Objective：To explore the clinical significance of serum vascular endothelial growth factor （VEGF） concentration in patients with advanced malignant tumors, nethods：ELISA assay was used to determine the protein concentration of serum VEGF in 40 cases with advanced malignant tumors （ non-small cell lung cancer, nasopharyngeal carcinoma, esophageal carcinoma） and 10 cases of healthy controls. Results ：The serum VEGF concentration in 40 cases with advanced malignant tumors were significantly higher than those of 10 healthy cases controls[ （477.07 ± 374. 10） pg/ml vs. （ 139.09 ± 133.41 ） pg/ml, P =0. 016]. The concentration of serum VEGF in patients with non-small cell lung cancer, nasopharyngeal carcinoma and esophageal carcinoma were （518. 53 ± 378. 99） pg/ml, （399. 21 ± 393.69 ） pg/ml and （500. 68 ± 348.48 ） pg/ml, respectively. The differences were all statistically significant compared with healthy control groups （P values were 0. 011, 0. 044 and 0. 019, respectively）, the concentration of serum VEGF in patients response to chemotherapy was significantly lower than pre-chemotherapy in patients with advanced malignant tumors[ （400. 41 ± 332.84） pg/ml vs. （777.10 ±666. 01 ） pg/ml, P =0. 034]. Conclusion：The serum VEGF level might be as a new tumor marker of advanced malignant tumors and predicts the progress of the disease and poor prognosis of patients.